Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
13
04
2021
accepted:
21
09
2021
entrez:
12
11
2021
pubmed:
13
11
2021
medline:
12
3
2022
Statut:
epublish
Résumé
Adapted ketogenic diet (AKD) and caloric restriction (CR) have been suggested as alternative therapeutic strategies for multiple sclerosis (MS), but information on their impact on neuroaxonal damage is lacking. Thus, we explored the impact of diets on serum neurofilament light chain (sNfL) levels in patients with relapsing-remitting MS. We retrospectively evaluated a prospective randomized controlled trial of 60 patients with MS who were on a common diet or ketogenic diet or fasting. We examined sNfL levels of 40 participants at baseline and at the end of the study after 6 months using single molecule array assay. sNfL levels were investigated in 9 controls, 14 participants on CR, and 17 participants on AKD. Correlation analysis showed an association of sNfL with age and disease duration; an association was also found between sNfL and the Multiple Sclerosis Functional Composite. AKD significantly reduced sNfL levels at 6 months compared with the common diet group ( For clinical or study use, consider that AKD may incline sNfL levels independent of relapse activity up to 3 months after initiation. At 6 months, AKD, which complements current therapies, reduced sNfL levels, therefore suggesting potential neuroprotective effects in MS. A single cycle of seven-day fasting did not affect sNfL. AKD may be an addition to the armamentarium to help clinicians support patients with MS in a personalized manner with tailored diet strategies. Clinical trial registration number NCT01538355.
Sections du résumé
BACKGROUND AND OBJECTIVES
Adapted ketogenic diet (AKD) and caloric restriction (CR) have been suggested as alternative therapeutic strategies for multiple sclerosis (MS), but information on their impact on neuroaxonal damage is lacking. Thus, we explored the impact of diets on serum neurofilament light chain (sNfL) levels in patients with relapsing-remitting MS.
METHODS
We retrospectively evaluated a prospective randomized controlled trial of 60 patients with MS who were on a common diet or ketogenic diet or fasting. We examined sNfL levels of 40 participants at baseline and at the end of the study after 6 months using single molecule array assay.
RESULTS
sNfL levels were investigated in 9 controls, 14 participants on CR, and 17 participants on AKD. Correlation analysis showed an association of sNfL with age and disease duration; an association was also found between sNfL and the Multiple Sclerosis Functional Composite. AKD significantly reduced sNfL levels at 6 months compared with the common diet group (
DISCUSSION
For clinical or study use, consider that AKD may incline sNfL levels independent of relapse activity up to 3 months after initiation. At 6 months, AKD, which complements current therapies, reduced sNfL levels, therefore suggesting potential neuroprotective effects in MS. A single cycle of seven-day fasting did not affect sNfL. AKD may be an addition to the armamentarium to help clinicians support patients with MS in a personalized manner with tailored diet strategies.
TRIAL REGISTRATION INFORMATION
Clinical trial registration number NCT01538355.
Identifiants
pubmed: 34764215
pii: 9/1/e1102
doi: 10.1212/NXI.0000000000001102
pmc: PMC8587737
pii:
doi:
Substances chimiques
Neurofilament Proteins
0
neurofilament protein L
0
Banques de données
ClinicalTrials.gov
['NCT01538355']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
EBioMedicine. 2018 Oct;36:293-303
pubmed: 30292675
Cell Rep. 2016 Jun 7;15(10):2136-2146
pubmed: 27239035
Front Microbiol. 2017 Jun 28;8:1141
pubmed: 28702003
Stroke. 2019 Nov;50(11):3077-3084
pubmed: 31537188
Seizure. 2016 May;38:17-22
pubmed: 27061881
EBioMedicine. 2020 Jun;56:102807
pubmed: 32460167
Mult Scler. 2019 Apr;25(5):678-686
pubmed: 29542376
Ann Clin Transl Neurol. 2020 Dec;7(12):2508-2523
pubmed: 33146954
PLoS One. 2012;7(5):e35476
pubmed: 22567104
Brain Res. 2018 Jan 1;1678:106-115
pubmed: 29056525
Autophagy. 2010 Aug;6(6):702-10
pubmed: 20534972
Mult Scler J Exp Transl Clin. 2020 Aug 27;6(3):2055217320936318
pubmed: 32922829
Toxicology. 2013 Aug 9;310:92-7
pubmed: 23743148